Management of biochemically recurrent prostate cancer can be determined by the use of nomograms based on risk factors, but this approach might not lead to selection of optimal courses of treatment for individual patients. Choline-PET–CT imaging can identify the sites of recurrence in these patients, enabling personalized treatment choices depending on the presence of localized or metastatic disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
Radiation Oncology Open Access 11 March 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldstein, J. et al. Does choline PET/CT change the management of prostate cancer patients with biochemical failure? Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC.0000000000000139.
Kattan, M. W., Wheeler, T. M. & Scardino, P. T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 17, 1499–1507 (1999).
Mohler, J. L. et al. Prostate cancer, version 1.2014. J. Natl Compr. Canc. Netw. 11, 1471–1479 (2013).
Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467–479 (2014).
Berkovic, P. et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin. Genitourin. Cancer 11, 27–32 (2013).
Suardi, N. et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.011.
Castellucci, P. et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? J. Nucl. Med. 55, 1424–1429 (2014).
Soyka, J. D. et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 39, 936–943 (2012).
Ceci, F. et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur. J. Nucl. Med. Mol. Imaging http://dx.doi.org/10.1007/s00259-014-2872-x.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Castellucci, P., Fanti, S. Identifying sites of recurrence with choline-PET–CT imaging. Nat Rev Urol 12, 134–135 (2015). https://doi.org/10.1038/nrurol.2014.321
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.321
This article is cited by
-
Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
Radiation Oncology (2016)
-
11C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series
European Journal of Nuclear Medicine and Molecular Imaging (2016)
-
PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
European Journal of Nuclear Medicine and Molecular Imaging (2016)
